An agreement could be announced as soon as Tuesday and would value Masimo, a maker of patient monitoring systems, at a premium to its almost $7 billion market capitalization at Friday’s close, the newspaper said. Neither Danaher nor Masimo immediately responded to the FT’s requests for comment.
The purchase would mark Danaher’s largest acquisition since its more than $21 billion takeover in 2020 of Cytiva, the biologics manufacturing unit ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.